tailieunhanh - Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab–paclitaxel or FOLFIRINOX: A post–hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study)

No reliable nomogram has been developed until date for predicting the survival in patients with unresectable pancreatic cancer undergoing treatment with gemcitabine plus nab–paclitaxel (GnP) or FOLFIRINOX. Methods: This analysis was conducted using clinical data of Japanese patients with unresectable pancreatic cancer undergoing GnP or FOLFIRINOX treatment obtained from a multicenter study (NAPOLEON study). | Shibuki et al. BMC Cancer 2022 22 19 https s12885-021-09139-y RESEARCH ARTICLE Open Access Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab paclitaxel or FOLFIRINOX A post hoc analysis of a multicenter retrospective study in Japan NAPOLEON study Taro Shibuki1 2 Toshihiko Mizuta1 3 Mototsugu Shimokawa4 5 Futa Koga6 Yujiro Ueda7 Junichi Nakazawa8 Azusa Komori9 Satoshi Otsu9 Shiho Arima10 Masaru Fukahori11 Akitaka Makiyama12 13 Hiroki Taguchi14 15 Takuya Honda16 Kenji Mitsugi17 18 Kenta Nio17 18 Yasushi Ide19 Norio Ureshino20 21 Tsuyoshi Shirakawa22 23 and Taiga Otsuka20 24 Abstract Background No reliable nomogram has been developed until date for predicting the survival in patients with unre- sectable pancreatic cancer undergoing treatment with gemcitabine plus nab paclitaxel GnP or FOLFIRINOX. Methods This analysis was conducted using clinical data of Japanese patients with unresectable pancreatic cancer undergoing GnP or FOLFIRINOX treatment obtained from a multicenter study NAPOLEON study . A Cox proportional hazards model was used to identify the independent prognostic factors. A nomogram to predict 6 12 and 18 month survival probabilities was generated validated by using the concordance index C index and calibrated by the bootstrapping method. And then we attempted risk stratification for survival by classifying the patients according to the sum of the scores on the nomogram total nomogram points . Results A total of 318 patients were enrolled. A prognostic nomogram was generated using data on the Eastern Cooperative Oncology Group performance status liver metastasis serum LDH serum CRP and serum CA19 9. The C indexes of the nomogram were and for 6 12 and 18 month survival respectively. The calibration plot showed optimal agreement at all points. Risk stratification based on tertiles of the total nomogram points yielded clear separations of the survival curves. The median .

• Y khoa - Dược
• BMC Cancer
• Unresectable pancreatic cancer
• Overall survival
• Gemcitabine plus nab–paclitaxel
• Individualized management
• Cancer patient pathways
• Colorectal cancer
• Lung cancer
• Breast cancer
• Prostate cancer
• Ovarian cancer
• Cancer detection
• Ovarian cancer symptoms
• Ovarian cancer signs
• Ovarian cancer tests
• Cancer biomarkers
• Pediatric cancer
• Familial cancer predisposition
• Hereditary cancer syndrome
• Genetic cancer susceptibility
• Advanced cancer
• Biliary tract cancer
• Multimodal intervention
• Pancreatic cancer
• Physical activity
• Breast cancer screening
• Familial breast cancer
• Young breast cancer survivors
• High risk relatives
• Randomized trial
• Childhood cancer
• Childhood cancer survivor
• Thyroid cancer screening
• Secondary cancer
• Cancer screening
• Community awareness
• Cancer education
• Cervical cancer
• Prior cancer
• Cancer survivors
• Cancer registry
• Second cancer
• Surgical oncology
• Cancer imaging
• Radiation oncologists
• Medical oncologists
• Oesophagogastric cancer
• Liver cancer
• Hepatobiliary cancer
• Multidisciplinary rehabilitation
• EGFR mutation
• Family history of cancer
• Inherited susceptibility
• Cancer predisposition genes
• Lung cancer aetiology
• Cancer stem cells
• Oct4 overexpressing lung cancer
• Human lung cancer xenograft model
• Disease free survivals
• Cancer hallmarks
• Cancer genesis
• Defiant disease
• Mutational signature
• Cancer diagnosis
• Cancer genomics
• Molecular medicine
• Whole genome sequencing
• Cancer susceptibility gene
• Breast cancer prognosis
• Next generation sequencing
• Quality of care
• Quality indicators
• Shifting cancer care
• German cancer society
• Colorectal cancer screening
• Stomach cancer screening
• Lung cancer survivor
• Physician recommendation
• Total number of lymph nodes
• Lymph node ratio
• Left colon cancer
• Right colon cancer
• Cumulative incidence
• Esophageal cancer
• Head and neck cancer
• Metachronous cancer
• Young onset
• Reproductive cancer
• Risk factor
• Early detection of cancer
• Gastric cancer incidence
• Population based specialized registry
• Gastric cancer survival
• Gastric cancer clinical characteristics
• Gastric cancer pathological characteristics
• Lung Cancer Screening
• Racial disparities
• Lung Cancer diagnosis
• Screening adherence
• Second primary colorectal cancer
• Standardized incidence ratio
• Left sided colon cancer
• Right sided colon cancer
• Quality of cancer care
• Population based study